טוען...
Pembrolizumab plus allogeneic NK cells in advanced non–small cell lung cancer patients
BACKGROUND: The anti–programmed cell death 1 (anti–PD-1) antibody pembrolizumab is clinically active against non–small cell lung cancer (NSCLC). In addition to T cells, human natural killer (NK) cells, reported to have the potential to prolong the survival of patients with advanced NSCLC, also expre...
שמור ב:
| הוצא לאור ב: | J Clin Invest |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Society for Clinical Investigation
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7190908/ https://ncbi.nlm.nih.gov/pubmed/32027620 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI132712 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|